

## PharmaNet Incorporated

[View the current PharmaNet Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/biocomplete/5459-PharmaNet+Incorporated.html)

(<http://www.bioportfolio.com/biocomplete/5459-PharmaNet+Incorporated.html>)

### Contact Details:

**504 Carnegie Center**

**Princeton**

**NJ**

**08540-6242**

**United States of America**

Tel: 609 951 6800

Fax: 609 514 0390

Email: [lallen@pharmanet-cro.com](mailto:lallen@pharmanet-cro.com)

PharmaNet is a full-service contract research organization (CRO) dedicated to providing exceptional drug development services on a global basis.

With offices strategically placed throughout the US, Europe and Asia, we provide a complete range of Phase I-IV clinical development services including strategic planning, data management and biostatistics, medical writing, site management and regulatory affairs.

PharmaNet's innovative use of the latest technologies provides efficiencies within the electronic process from data capture through global electronic regulatory submissions.

Additionally, PharmaNet offers a variety of clinical trial consulting services for all aspects of your pharmaceutical and biotechnology drug development activities including extended services relating to toxicology, chemistry and manufacturing, preclinical and clinical pharmacokinetics and the assessment of in-licensing candidates.

### Recent Publications by PharmaNet Incorporated:



- [Basic principles of stability.](#)

*An understanding of the principles of degradation, as well as the...*2nd September, 2009

Pharmanet- Biologicals. 2009 Nov;37(6):379-86; discussion 421-3. Epub 2009 Aug 31. ([DOI Direct Link](#))

- [\[Mumps--effect of immunizations on epidemiological situation\]](#)

*In 2004, 57% of States included mumps vaccine in their routine national...*29th January, 2009

Instytut "Centrum Zdrowia Matki Polki" w Lodzi III Klinika Pediatrii.- Przegl Epidemiol.

2008;62(3):613-21.

- [Growth hormone therapy in children and adults.](#)

- Growth hormone (GH) is a polypeptide hormone, secreted by somatotropic...* 19th November, 2008  
Department of Internal Medicine and Clinical Pharmacology, Medical- Pharmacol Rep. 2007  
Sep-Oct;59(5):500-16.
- [\[Etiology, histopathological picture and clinical presentation of craniopharyngioma\]](#)  
*Craniopharyngioma is a rare, benign, suprasellar brain tumour accounting...* 14th November, 2008  
Slaski Uniwersytet Medyczny, Klinika Chorob Wewnętrznych i Farmakologii- Pol Merkur Lekarski. 2008  
Aug;25(146):175-8.
  - [\[Rare pancreatic endocrine tumors\]](#)  
*Functional pancreatic endocrine tumors other than gastrinoma and...* 8th November, 2008  
Klinika Chorob Wewnętrznych i Farmakologii Klinicznej, Slaski Uniwersytet- Przegl Lek.  
2008;65(4):209-16.
  - [\[Current views on the role of dehydroepiandrosterone in physiology, pathology and therapy\]](#)  
*Dehydroepiandrosterone (DHEA) and its sulfate metabolite (DHEAS) are the...* 17th October, 2008  
Slaska Akademia Medyczna w Katowicach, Klinika Chorob Wewnętrznych i- Pol Merkur Lekarski. 2008  
Jan;24(139):66-71.
  - [\[Commentary to the article: Wiviott S D, Braunwald E, McCabe C H et al. Prasugrel versus clopidogrel in patients with acute coronary syndrome. N Engl J Med 2007; 357: 2001-15\]](#)  
*Dehydroepiandrosterone (DHEA) and its sulfate metabolite (DHEAS) are the...* 30th August, 2008  
Samodzielna Pracownia Hemodynamiki, Instytut Kardiologii, Warszawa.- Kardiol Pol. 2008  
Feb;66(2):222-5; discussion 225-6.
  - [\[Ghrelin agonist \(TZP-101\): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study.\]](#)  
*The authors evaluate the human safety, tolerability, pharmacokinetics, and...* 20th May, 2008  
Pharmanet Development Group, Inc., Miami, Florida, USA.- J Clin Pharmacol. 2008  
Feb;48(2):193-202. ([DOI Direct Link](#))
  - [\[Somatostatin analogs\]](#)  
*Hypothyroidism is a fairly common disease. The signs and symptoms of...* 16th May, 2008  
Katedra Farmakologii, Zaklad Farmakologii Klinicznej S1. AM w Katowicach.- Pol Arch Med Wewn.  
2006 Oct;116(4):988-97.
  - [\[Finger cooling test and psychometric analysis in thyroid auxiliary diagnostics.\]](#)  
*Hypothyroidism is a fairly common disease. The signs and symptoms of...* 15th May, 2008  
Computer Science Department, University of Silesia, Sosnowiec, Poland.- Acta Bioeng Biomech.  
2007;9(2):61-8.
  - [\[Cellular transplantation--orthotopic liver transplantation alternative\]](#)  
*Hepatocyte transplantation is a promising treatment for several liver...* 15th March, 2008  
Dolnoslaskie Centrum Transplantacji Komorkowych z Krajowym Bankiem Dawcow- Pol Merkur  
Lekarski. 2007 Oct;23(136):297-301.
  - [\[Serum level of YKL-40 does not predict advanced liver fibrosis in children with chronic hepatitis B.\]](#)  
*PURPOSE: The aim of the study was to evaluate the serum concentration of...* 1st March, 2008  
IIIrd Department of Pediatrics, Medical University of Bialystok, ul.- Adv Med Sci. 2007;52:120-4.
  - [\[Matrix metalloproteinases and their tissue inhibitors in children with chronic hepatitis B treated with lamivudine.\]](#)  
*PURPOSE: To evaluate if measurements of MMP-2, MMP-9, TIMP-1 and TIMP-2...* 1st March, 2008  
III Department of Pediatrics, Medical University of Bialystok, Poland.- Adv Med Sci. 2007;52:114-9.
  - [\[The testosterone therapy in patients with andropause\]](#)  
*Andropause affects millions of men worldwide. The importance of this...* 9th February, 2008  
Kliniki Chorob Wewnętrznych i Farmakologii Klinicznej Katedry Farmakologii- Wiad Lek.  
2007;60(7-8):356-64.

**Press Releases on PharmaNet Incorporated:**

[Aflac To Exchange Two Lloyds Banking Group Securities, Enhance Risk-Based Capital Ratio](#)

24th November, 2009 Aflac Incorporated

COLUMBUS, Ga., Nov. 24 /PRNewswire-FirstCall/ -- Aflac Incorporated (NYSE: AFL) announced today that the Lloyds Banking Group plc has accepted the exchange of two of its investment securities owned by

[WellTek Positioned to Capitalize on Trends in Health and Fitness](#)

24th November, 2009 WellTek Incorporated

ORLANDO, Fla., Nov. 24 /PRNewswire-FirstCall/ -- Two thirds of adults are overweight and one third of those are obese. Experts estimate that 80 percent of the population will experience a back

[Wellcore to Introduce Consumer Technology Products that Promote Health and Wellness](#)

24th November, 2009 Wellcore Corporation

SAN JOSE, Calif., Nov. 24 /PRNewswire/ -- Wellcore Corporation, a Silicon Valley-based company dedicated to developing wireless products and services that promote wellness, safety and security, is

[Accuray Incorporated to Present at Piper Jaffray Healthcare Conference and J. P. Morgan Small/Mid Cap Conference](#)

23rd November, 2009 Accuray Incorporated

SUNNYVALE, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that its management is scheduled to present at

[H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics](#)

20th November, 2009 Quest Diagnostics Incorporated

-- Rates of positive test results for the pandemic have declined in recent weeks in most regions, with the exception of the Northeast, where rates have more than doubled during

## BioNews Results for PharmaNet Incorporated



- [Phase Forward signs agreement with PharmaNet Development Group](#)  
*Pharmacy Choice: Nov 6 2009 7:01PM Matching: pharmanet*
- [Phase Forward Teams with PharmaNet Development Group](#)  
*Forbes.com: Nov 4 2009 8:26AM Matching: pharmanet*
- [Phase Forward Teams with PharmaNet Development Group - Zibb.com](#)  
*Zibb: Nov 4 2009 9:25AM Matching: pharmanet*
- [Phase Forward Teams with PharmaNet Development Group](#)

- [Phase Forward Teams with PharmaNet Development Group](#)  
*Street Insider: Nov 4 2009 8:13AM Matching: pharmanet*
- [Phase Forward Teams with PharmaNet Development Group](#)  
*Street Insider: Nov 4 2009 8:13AM Matching: pharmanet*
- [Phase Forward Teams with PharmaNet Development Group](#)  
*Centre Daily Times: Nov 4 2009 8:59AM Matching: pharmanet*
- [Phase Forward Teams with PharmaNet Development Group](#)  
*Genetic Engineering News: Nov 4 2009 8:49AM Matching: pharmanet*
- [Phase Forward Teams with PharmaNet Development Group](#)  
*Earthtimes.org: Nov 4 2009 8:23AM Matching: pharmanet*
- [Phase Forward Teams with PharmaNet Development Group](#)  
*Earthtimes.org: Nov 4 2009 8:23AM Matching: pharmanet*
- [Phase Forward Teams with PharmaNet Development Group](#)  
*Earthtimes.org: Nov 4 2009 8:22AM Matching: pharmanet*
- [Phase Forward Teams with PharmaNet Development Group](#)  
*Pharma Live: Nov 4 2009 11:30PM Matching: pharmanet*
- [Phase Forward Teams with PharmaNet Development Group](#)  
*Pharmacy Choice: Nov 4 2009 3:12PM Matching: pharmanet*
- [Phase Forward Teams with PharmaNet Development Group](#)  
*FinanzNachrichten.de: Nov 4 2009 8:12AM Matching: pharmanet*
- [Phase Forward Teams with PharmaNet Development Group](#)  
*FinanzNachrichten.de: Nov 4 2009 8:12AM Matching: pharmanet*
- [Phase Forward Teams with PharmaNet Development Group](#)  
*TransWorldNews: Nov 4 2009 3:30PM Matching: pharmanet*

#### PharmaNet Incorporated Clinical Trials:



- [Imaging Study of XERECEPT® Treatment for Peritumoral Brain Edema \(PBE\)](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service

- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

